Scrutiny Of EpiPen Pricing Invited By Mylan Lobbying, Congressman Says
House Oversight Committee’s diatribe against Mylan has been fueled by the company’s efforts to engage lawmakers to advance its business interests, Rep. Mulvaney tells CEO Bresch: 'You asked for it.'
You may also be interested in...
Rep. Diana DeGette, new chair of US House Energy and Commerce Committee's Subcommittee on Oversight and Investigations, said insulin is a good example of problems with drug pricing and promised to call drug company CEOs to hearings.
Energy & Commerce Health Subcommittee is considering a hearing, but leadership may be concerned Democrats will use the session to air grievances over Republican efforts to repeal the Affordable Care Act.
Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.